The beneficial effect of chloroquine in the treatment of rheumatoid arthritis was established by long-term controlled trials,'12 but reports of retinal toxicity resulted in the drug falling into disfavour.3 The incidence ofchloroquine retinopathy has varied from less than 1 % 5 to 16 %6 in different series depending on the techniques used to establish the diagnosis.
The beneficial effect of chloroquine in the treatment of rheumatoid arthritis was established by long-term controlled trials,'12 but reports of retinal toxicity resulted in the drug falling into disfavour.3 The incidence ofchloroquine retinopathy has varied from less than 1 % 5 to 16 %6 in different series depending on the techniques used to establish the diagnosis.
Early studies suggested that the risk of chloroquine retinopathy is related to the total dose and total duration of treatment,'-9 and this cumulative effect may be explained by its slow excretion'0 and preferential accumulation in the pigmented layers of the eye." In animals the risk of chloroquine retinotoxicity is related to the daily dose,'2 and this correlates with the nonlinear rapid increase in chloroquine binding to melanin at increasing concentrations of the drug.13 Mackenzie and Scherbel14 suggested that the rate of administration governs the incidence of retinopathy, and there is a threshold level for the daily dose below which visual impairment does not occur irrespective of the cumulative drug consumption or the duration of treatment. In a recent retrospective study15 on ophthalmic complications in 222 patients on longterm treatment with chloroquine a reduction in visual acuity was found in only 1 patient who had received 500-750 mg daily, and this suggested that the risk of serious visual impairment is negligible provided the daily dose does not exceed 250 mg. In the present study an attempt has been made to confirm or refute this observation, because it would have important implications on the necessity for regular ophthalmic supervision. This question cannot be resolved by a prospective study, since it would be unethical to continue treatment, in spite of possible abnormalities in retinal screening tests, until visual acuity became impaired. The alternative is to ascertain retrospectively those patients who developed visual impairment while on chloroquine with particular reference to the daily dose they had been receiving.
Materials and methods
All case reports of chloroquine retinopathy published in English were reviewed and the relationship between daily dose and ocular toxicity assessed from those reports in which the daily dose was stated and visual acuity was impaired.6 8 was possible to examine the relationship between of treatment, and these were unlikely to be the the daily dose and visual impairment ( Table 1) . result of a retinopathy. One patient (case 6) had Chloroquine retinopathy associated with visual been taking chloroquine intermittently for 2 years for impairment was reported in only 13 cases where the malaria chemoprophylaxis and developed sudden daily dose did not exceed 250 mg, and in 3 of these deterioration in vision, but iL is unclear whether this the patients had also received other antimalarials. was the result of a retinopathy. There were 2 patients The remaining case reports all referred to patients (cases 1, 2) who developed an unquestionable who had received more than 250 mg daily: 47 chloroquine retinopathy associated with visual received up to 500 mg daily, 15 up to 750 mg daily, impairment, and both had received daily doses of and 3 more than 750 mg daily.
250 mg or less.
There were 11 reports of chloroquine retinopathy A postal questionnaire was sent to 45 rheumato the CSM ( Table 2) . Five of these (cases 1,2, 6, 8,9) tology centres and replies were received from 41. were stated to have visual impairment, but 2 (cases Twenty-three centres had no cases of ocular 8, 9) developed eye symptoms after only a few days toxicity, but 11 of these commented that chloro- (Table   4) . One patient (case 2) had taken chloroquine phosphate 250 mg daily for 7 years for nocturnal cramps and developed typical features of chloroquine retinopathy associated with loss of vision. Another patient (case 3) who became blind was stated to have received chloroquine phosphate 100 mg twice daily, but tablets of chloroquine containing 100 mg in chloroquine phosphate have never been available in the United Kingdom, and she was probably receiving 250 mg twice daily.
Discussion
The major hazard associated with the use of chloroquine is retinopathy, which may be irreversible17 2224 or may progress after treatment is discontinued.21 31 Many rheumatologists are reluctant to use antimalarials, and the British National Formulary 1976-8 condemns their use and states that chloroquine 'is now regarded as obsolete. ' The retinopathy may be reversible if diagnosed in the early stages,33 42 43 but there is disagreement about which methods should be used to establish the diagnosis. The earliest retinal change is abnormal pigmentation around the macula, referred to as stippling or mottling, but there is a wide variation in normal macular appearance, and similar changes may occur in the aging eye44 and have also been found in rheumatoid patients who have never received chloroquine.4 45 In the well-established chloroquine retinopathy there are concentric rings of hyperpigmentation anddepigmentation aroundthe macula producing a bull's eye appearance, but this configuration is not pathognomonic of chloroquine toxicity46 and was probably a chance finding in one of the patients reported in this study (Table 3 , case 5).
The unreliability of fundus examination may explain the multiplicity of other techniques which have been advocated in the diagnosis of chloroquine retinopathy. Visual field examination characteristically shows a pericentral scotoma to a red target,47 but there is a 6 % incidence of red scotomata in the normal population,48 and accurate testing of visual acuity requires a co-operative patient. Tests of colour vision may be used as a screening test for macular damage,43 but some patients have normal colour vision in the presence of macular mottling and scotomata,6 8 and colour discrimination may be abnormal in rheumatoid patients who have never received chloroquine.49 There have been enthusiastic claims for the value of electroretinographyW and electro-oculography,51 52 56 and dark adaptometry,57 but abnormalities in these tests may be age-related and are not specific for chloroquine retinotoxicity.46 4958 The reliability of ophthalmic assessment might be improved by performing a battery of tests,6 but this would be time consuming and is impracticable for monitoring most patients. There is therefore no completely reliable means of diagnosing chloroquine retinopathy before serious visual impairment has occurred.
The review of published case reports on chloroquine retinopathy ( Table 1 ) has confirmed that the major risk of visual impairment relates to those patients receiving a daily dose above 250 mg. There were only 13 reported cases of patients developing a permanent reduction in visual acuity on a daily dose of 250 mg, and 3 of these had previously received other antimalarials. Mayer26 reported the case of a 30-year-old woman with rheumatoid arthritis who developed impaired vision on 250 mg daily but commented that she had received a total dose of 782 g over 3k years, which means she was probably receiving 500 mg daily. The results of the postal questionnaire completed by rheumatologists at 41 centres in Great Britain showed that serious retinal problems rarely occurred as a result of chloroquine therapy and visual impairment was reported in only 13 cases. Six patients had unequivocal evidence that their visual impairment was the result of a chloroquine retinopathy, but 5 of these had been receiving daily doses of chloroquine phosphate above 250 mg. In 3 other cases the visual impairment was probably coincidental to chloroquine therapy. There was therefore only 1 patient (Table 3 , case 7) on chloroquine 250 mg daily who developed impaired vision as a result of treatment.
The postal questionnaire was completed by ophthalmologists at 33 centres. Eight patients treated with chloroquine developed impaired vision, but details were available in only 3, and only 1 of these (Table 4 , case 2) had been receiving chloroquine 250 mg daily. There was therefore little evidence from ophthalmic sources that chloroquine use in Great Britain is causing visual problems.
The purpose of this study was to establish whether there is a safe daily dose of chloroquine which does not lead to impaired vision. From a review of cases from 3 different sources, namely, published case reports, reports to the CSM, and from personal communication with British rheumatologists and ophthalmologists, the risk of visual impairment associated with chloroquine therapy appears to be very small provided the daily dose does not exceed 250 mg. But occasional cases may occur at this dose level, so that ophthalmic supervision should still be undertaken.
I thank the members of the Heberden Society and Othalmological Society of the United Kingdom for their replies to the questionnaire on chloroquine retinopathy.
